11^th Annual Conference on Stem Cell and Regenerative Medicine October 15-16, 2018 Amsterdam, Netherlands

Mr. Deven Patel, the CEO, President and Cofounder of Global Institute of Stem Cell Therapy and Research (GIOSTAR) with headquarter in San Diego, California, U.S.A. GIOSTAR was formed with the vision to provide affordable stem cell based therapies to the masses around the world suffering from degenerative or genetic diseases and unable to afford today’s high cost of the treatment. He was honored with USA Congressional Recognition for his efforts in spreading the advancement of stem cell science around the world. He was also bestowed upon Asian Heritage Award for his business leadership in the field of stem cell science. GIOSTAR under the leadership of Mr. Patel is in charge of developing stem cell transplant program for four different State Governments in India with total population of approx. 155 million. GIOSTAR, in collaborations with Government of Gujarat, India, world's largest state of the art Stem Cell Treatment Hospital in India. GIOSTAR is in process of developing its facility in China, Thailand, Colombia, Bahamas, Dubai and Austalia.

The Stem Cell Therapy and Its Emerging Markets

Dr.Eugene Zadorin has completed his PhD at the age of 28 years from Cardiology University. He is the director of NBScience, a premier contract research organization. He has published more than 40 papers in reputed journals and has been serving as an editorial board member of repute.

Stem cells therapy is a relatively new and promising direction in the treatment of many serious diseases in which conventional methods fail to achieve the desired results. In the therapeutic aspect of the pathology of the gastrointestinal tract and liver, the most promising at this stage are inflammatory bowel diseases, colorectal cancer and decompensated cirrhosis of the liver. At the same time, clinical application of the embryonic stem cells involves a number of ethical and religious limitations. In contrast to embryonic stem cells, autologous stem cells of the patient is ethical and promising, as it opens up unlimited possibilities of repair, regeneration of tissues, amplification and modeling of the immune system, rejuvenation of all tissues and organs.

Vasilis has worked at and consulted for a number of pharmaceutical and biotech companies globally. Due to his innovation he has been the founder and director of seven biotech companies since 2000, including Adistem, Paspa Pharmaceuticals, Black Arrow Biotech and Nereen Healthcare. In early 2006, he founded Adistem, Ltd in Hong Kong. After finishing his doctorate in pharmacology/endocrinology in 1993 at St Vincent’s Institute of Medical Research at the University of Melbourne, he completed his post-doctoral fellowship at Pfizer Central Research, Pfizer Inc., in Groton, Connecticut. During this time he was given two scholarships from the Australian Federal Government, and the National Health and Medical research Council of Australia. Dr. Paspaliaris has published over 20 papers, holds over 5 patents and given lectures in a variety of medical fields, mostly in stem cell medicine. He is currently a Faculty Member for the Masters degree program in Clinical Pharmacology and Therapeutics at Democritus University Medical School and the University of Crete in Greece. He is a member of the World Society of Interdisciplinary Anti-aging Medicine, the Australian Military Medicine Association and Latin American Stem Cell Society, New York Academy of Sciences, Australian Institute of Directors, a Fellow of the Philippine Society of Stem Cell Medicine and a Fellow of the Royal Society of Medicine (UK). He is currently also completing his MBA at the Australian Institute of Business.

Anti-Aging Medicine and Cancer Research

Dr. Choudhery earned a BS (Hons) degree from the University of Punjab in 2007. He completed his Mphil and Doctorate from National Center of excellence in Molecular Biology (CEMB) in 2012. He completed a part of his research work in Professor David Harris’s Laboratory at College of Medicine, Department of Immunology, The University of Arizona, Tucson, USA. Dr. Choudhery also worked as Post-doctorate Fellow at the College of Medicine, Department of Immunology, The University of Arizona, Tucson, USA. In December 2012 he joined the faculty at the King Edward Medical University as an Assistant Professor. Dr. Choudhery’s research interests include clinical applications of stem cells, caloric restriction, tissue engineering, stem cell transplantation and gene therapy. Further he has a great interest in developing cell-free stem cell based therapies. He has published several research articles in peer reviewed international journals. Currently he is serving as a reviewer and editorial board member of more than 15 international Journals.

Stem cell based regenerative therapies, Tissue Engineering and Regenerative Medicine, stem cell transplantation and gene therapy, Cell-free stem cell based therapies

Hassan El Yaqine holds a Master’s degree in biology, resource management and education from Vrije Universiteit in Amsterdam. He is the CEO and founder of Stem Cells Technologies with a laboratory in Zaandam Netherlands and one coming soon in Ras al khaimah.

Hematopoietic Stem Cells and Mesenchymal Stem Cells.